Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
a 19.2 · New Chemotherapy Agents 239<br />
and its liposomal cousin. Whereas the half-life of free<br />
vincristine is only 10 minutes, it is up to 8 h with the<br />
liposomal preparation [6]. Liposomal vincristine has<br />
been studied successfully in lymphoma salvage, as part<br />
of the CHOP (cyclophosphamide, adriamycin, vincristine,<br />
prednisone) plus rituximab regimen in Non-Hodgkin’s<br />
lymphoma (NHL) patients, and in early clinical<br />
studies in ALL salvage.<br />
Liposomal vincristine was well tolerated and<br />
achieved a response rate of 35% in patients with relapsed<br />
and refractory NHL [7]. In a more recent update<br />
important predictors of response included number of<br />
prior regimens and sensitivity to the most recent treatment<br />
regimen. Response rates of up to 64% were reported<br />
in those patients with sensitive disease and not<br />
more than two prior regimens [8]. Rodriguez et al. substituted<br />
liposomal vincristine for free vincristine and<br />
investigated the liposomal preparation as part of the<br />
CHOP plus rituximab combination in patients with previously<br />
untreated NHL [9]. Patients received standard<br />
doses of CHOP, which included liposomal vincristine<br />
at 2 mg/m 2 (no dose capping). Of 68 patients who were<br />
evaluable for response 63 (93%) responded, which included<br />
62 patients with complete remission (CR), one<br />
with unconfirmed CR and one patient with partial response.<br />
At a median follow up of 29.5 months, median<br />
progression-free survival (PFS) and overall survival<br />
(OS) have not been reached. The treatment was well tolerated<br />
with only mild neurotoxicity. In a small study in<br />
ALL of single-agent liposomal vincristine at 2 mg/m 2<br />
given every 2 weeks, responses occurred in two of 14<br />
(14%) evaluable relapsed/refractory patients [10]. In a<br />
more recent phase I trial for patients with relapsed<br />
and refractory ALL, liposomal vincristine (dose range<br />
1.5 mg/m 2 to 2.25 mg/m 2 ) weekly for four doses per<br />
course was given in combination with pulse dexamethasone<br />
(40 mg daily on days 1–4 and 11–14) [11]. Of 14 evaluable<br />
patients, 4 (29%) achieved CR extending through<br />
all dose levels, and another two (14%) achieved hematologic<br />
improvement. Almost all patients experienced<br />
peripheral neuropathy, which did not exceed grade 2<br />
on the NCI Common Toxicity scale. The study is ongoing.<br />
Once the MTD has been defined, substitution<br />
of vincristine for the liposomal preparation in ALL induction<br />
protocols such as the hyper-CVAD regimen is<br />
planned.<br />
19.2.2 Nucleoside Analogs<br />
Since their establishment as antitumor drugs in the<br />
1960s, nucleoside analogs have been among the most<br />
active agents for patients with cancer. In addition to<br />
the established and more traditional nucleoside analogs<br />
such as cytarabine, fludarabine, cladribine, or pentostatin,<br />
new nucleoside analogs are emerging that demonstrate<br />
additional metabolic properties and mechanisms<br />
of actions, and their activity is currently evaluated in<br />
clinical trials including in patients with ALL [12].<br />
Nelarabine (compound 506U78, ara-G) is the<br />
water-soluble prodrug of the deoxyguanosine analog<br />
guanosine arabinoside (ara-G) [13]. Nelarabine is not<br />
active by itself and requires conversion to ara-G by<br />
the enzyme adenosine deaminase, which is an efficient<br />
enough process to result in cytotoxic levels of ara-<br />
GTP in circulating leukemia cells. It has been demonstrated<br />
that ara-GTP is accumulated at higher levels in<br />
T lymphoblasts than in myeloblasts or B lymphoblasts.<br />
In addition, it has been shown in human leukemia<br />
cell lines that cytotoxicity to T lymphoblasts was<br />
increased with greater accumulation and more prolonged<br />
retention of ara-G in these cells [14–17]. Several<br />
early clinical trials of nelarabine have been conducted<br />
in refractory acute and chronic leukemias. Using a<br />
schedule of 1200 mg/m 2 or more daily for up to<br />
5 days, response rates of 40–50% have been reported<br />
in refractory T-cell ALL. At most of these schedules,<br />
neurotoxicity (including seizures, obtundation, ascending<br />
paralysis) was the DLT and the maximum-tolerated<br />
dose (MTD) in adults has been established at<br />
40 mg/kg/day for 5 days [18].<br />
Alternative schedules and doses are therefore being<br />
explored. To reduce the risk of neurotoxicity, the CALGB<br />
and SWOG investigated a nelarabine schedule of 1.5 g/<br />
m 2 /day given on days 1, 3, and 5 every 21 days [19].<br />
Forty patients (22 ALL and 18 lymphoblastic lymphoma<br />
[LL]) were enrolled. All patients were refractory to at<br />
least one induction regimen or were in first or subsequent<br />
relapse without demonstrable CNS disease. Of<br />
21 evaluable ALL patients, the OR was 38% (including<br />
six CR patients). For the group of LL patients, 24% responded<br />
(including four CR) for an overall response<br />
rate of 38% in 38 evaluable patients. Myelosuppression<br />
was the main toxicity with minimal neurotoxicity reported.<br />
The median DFS for the CR patients was<br />
9.8 months. The POG/CCG Intergroup investigated nelarabine<br />
in patients with relapsed and refractory T-cell